<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107622</url>
  </required_header>
  <id_info>
    <org_study_id>Lp + PD</org_study_id>
    <nct_id>NCT05107622</nct_id>
  </id_info>
  <brief_title>Administration of L. Paracasei 28.4 as an Adjunct to the Treatment of Periodontitis</brief_title>
  <official_title>Administration of L. Paracasei 28.4 as an Adjunct to the Treatment of Periodontitis: Superiority Placebo-controlled Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Estadual Paulista Júlio de Mesquita Filho</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Estadual Paulista Júlio de Mesquita Filho</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects of probiotic administration of L. paracasei&#xD;
      28.4 as an adjunct to the non-surgical periodontal treatment in patients with periodontitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a superiority placebo-controlled randomized clinical trial. The population that will&#xD;
      be evaluated in the study will be selected at Institute of Science and Technology (ICT), São&#xD;
      José dos Campos, College of Dentistry.&#xD;
&#xD;
      Sixty patients presenting Stage II/III/IV and Grade A/B periodontitis will be divided into 2&#xD;
      groups:&#xD;
&#xD;
        -  FMUD+Placebo (n=30): full-mouth ultrasonic periodontal debridement associated with&#xD;
           administration of placebo formulation, twice a day for 30 days;&#xD;
&#xD;
        -  FMUD+Probiotic (n=30): full-mouth ultrasonic periodontal debridement associated with&#xD;
           administration of probiotic formulation twice a day for 30 days.&#xD;
&#xD;
      The study will consist of two stages of treatment:&#xD;
&#xD;
        -  Initial therapy: Before starting treatment, a complete examination of the oral cavity&#xD;
           and evaluation of periodontal parameters will be performed. All patients will undergo a&#xD;
           prior adjustment of the oral environment and oral hygiene. Thirty days after completion&#xD;
           of initial therapy, a new periodontal evaluation will be performed and only patients who&#xD;
           present a visible plaque index less than or equal to 25% will undergo subgingival&#xD;
           periodontal debridement.&#xD;
&#xD;
        -  Non-surgical periodontal therapy: After initial therapy, all patients will receive&#xD;
           full-mouth ultrasonic periodontal debridement. Debridement will be performed by a single&#xD;
           operator, trained, blind to the allocation of patients and different from the evaluator.&#xD;
           If there is any complication that prevents the completion of full-mouth debridement, the&#xD;
           procedure will be finished within a maximum period of 24 hours. The randomization&#xD;
           envelope will be opened and the probiotic/placebo formulation will be delivered to&#xD;
           patients. They will be instructed to consume the samples twice a day during the 30 days&#xD;
           following periodontal treatment.&#xD;
&#xD;
      All clinical measurements will be performed by a single researcher, previously calibrated for&#xD;
      the measurements. After periodontal therapy, treatment results will be evaluated three and&#xD;
      six months after periodontal debridement associated with the use of placebo/probiotic&#xD;
      formulation. Indications of adverse oral effects will be verified by visual assessment at 7,&#xD;
      30 and 90 days after the start of consumption of formulations.&#xD;
&#xD;
      To assess patient-centered parameters, the OHIP-14 questionnaire will be applied before and&#xD;
      after 6 months of periodontal treatment for each patient. A 30-days diary will be used to&#xD;
      assess the adherence to use and occurrence adverse effects.&#xD;
&#xD;
      Microbiological and immunological analyzes will be carried out through subgingival biofilm&#xD;
      and gingival crevicular fluid samples collected from sites with moderate pockets and sites&#xD;
      with deep pockets at baseline, 3 and 6 months after therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of pockets with PD ≥ 5 mm</measure>
    <time_frame>6 months</time_frame>
    <description>Number of pockets with probing depth ≥ 5 mm</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>FMUD+Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMUD+Probiotic (n=30): full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation twice a day for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMUD+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FMUD+Placebo (n=30): full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation, twice a day for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMUD+Probiotic</intervention_name>
    <description>Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.</description>
    <arm_group_label>FMUD+Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FMUD+Placebo</intervention_name>
    <description>Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.</description>
    <arm_group_label>FMUD+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of stage II/III/IV and grade A/B generalized periodontitis;&#xD;
&#xD;
          -  Presence of at least 20 teeth in the mouth;&#xD;
&#xD;
          -  Signing the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of systemic conditions that contraindicate the periodontal procedure or&#xD;
             influence the progression of the disease;&#xD;
&#xD;
          -  Periodontal treatment history in the last six months;&#xD;
&#xD;
          -  Use of antibiotics or probiotics in the last six months;&#xD;
&#xD;
          -  Smoke more than 10 cigarettes a day;&#xD;
&#xD;
          -  Pregnant or breastfeeding;&#xD;
&#xD;
          -  Chronic use of anti-inflammatory drugs or medications that can alter the response of&#xD;
             periodontal tissues;&#xD;
&#xD;
          -  Need of antibiotic prophylaxis for dental procedures;&#xD;
&#xD;
          -  Need of probiotic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laís F Ferraz, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Paulo State University - Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro P Santamaria, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sao Paulo State University - Brazil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mauro P Santamaria, PhD</last_name>
    <phone>(12) 39479055</phone>
    <phone_ext>+55</phone_ext>
    <email>mauro.santamaria@unesp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laís FF Ferraz, MS</last_name>
    <phone>(15) 991756747</phone>
    <phone_ext>+55</phone_ext>
    <email>lais.ferraz@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mauro Pedrine Santamaria</name>
      <address>
        <city>São José dos Campos</city>
        <state>São Paulo</state>
        <zip>12245000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laís FF Ferraz, MS</last_name>
      <phone>(15) 991756747</phone>
      <phone_ext>+55</phone_ext>
      <email>lais.ferraz@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ribeiro FC, Junqueira JC, Dos Santos JD, de Barros PP, Rossoni RD, Shukla S, Fuchs BB, Shukla A, Mylonakis E. Development of Probiotic Formulations for Oral Candidiasis Prevention: Gellan Gum as a Carrier To Deliver Lactobacillus paracasei 28.4. Antimicrob Agents Chemother. 2020 May 21;64(6). pii: e02323-19. doi: 10.1128/AAC.02323-19. Print 2020 May 21.</citation>
    <PMID>32253208</PMID>
  </reference>
  <reference>
    <citation>Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172. doi: 10.1002/JPER.18-0006. Review. Erratum in: J Periodontol. 2018 Dec;89(12):1475.</citation>
    <PMID>29926952</PMID>
  </reference>
  <reference>
    <citation>Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2013 Nov;40(11):1025-35. doi: 10.1111/jcpe.12155. Epub 2013 Sep 15.</citation>
    <PMID>24164569</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Estadual Paulista Júlio de Mesquita Filho</investigator_affiliation>
    <investigator_full_name>Mauro Pedrine Santamaria</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available at the end of the study after a direct request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After the study completion.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

